NCT03049189 2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
Clinical Trials
69 trialsNCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT03659136 2025-02-24
The XENERAâ„¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Boehringer Ingelheim
Phase 2 Completed
NCT02842749 2025-02-10
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Phase 4 Completed
NCT03312738 2024-01-23
BOLERO-5
Novartis
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02264665 2023-11-13
OPALINE
Pfizer
Completed
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT03163667 2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT03525834 2021-09-09
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT00702052 2021-05-25
PILLAR-1
Novartis
Phase 2 Completed
NCT02732119 2021-05-05
TRINITI-1
Novartis
Phase 1/2 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT01231659 2021-03-26
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT01059318 2020-11-19
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Novartis
Phase 2 Completed
NCT02017860 2020-04-30
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Novartis
Phase 2 Completed
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT01743560 2019-07-18
4EVERUK
Novartis
Phase 4 Completed
NCT01206764 2019-06-24
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Novartis
Phase 4 Completed
NCT00419159 2019-04-23
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Novartis
Phase 2 Completed
NCT02454478 2019-03-19
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Eisai Inc.
Phase 1 Completed
NCT01136733 2019-02-27
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Eisai Inc.
Phase 1/2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00688623 2019-01-25
RAMSETE/CDE16
Novartis
Phase 2 Completed
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT01595009 2018-11-29
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Novartis
Phase 4 Completed
NCT01713946 2018-11-07
EXIST-3
Novartis
Phase 3 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT01514448 2017-07-19
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis
Phase 4 Completed
NCT00790036 2017-07-12
PILLAR2
Novartis
Phase 3 Completed
NCT01379521 2017-05-03
TRACER
Novartis
Phase 2 Terminated
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT01007942 2017-04-05
BOLERO-3
Novartis
Phase 3 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed